Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Introduction to eyesafe

1,230 views

Published on

Healthe works in collaboration with the medical community to design, develop and create EyeSafe™ digital light emission products for a global audience. As users screen time grows so does the lasting effects of exposure to High Energy Visible Light (HEV) Blue light emissions. Over 90% of the adult users that use a screen 3 hours or more on a daily basis are affected by Computer Vision Syndrome, symptoms include dry eyes, blurry vision, headaches, fatigue, double vision and eyestrain. Digital light also impacts a human’s sleep cycle by suppressing melatonin and disrupting one’s sleep patterns that ultimately affects behavior and productivity in both adults and children. Long-term exposure can lead to macular degeneration of the retina and premature aging of the retina causing ocular health problems that may not be restored. Since the invent of the digital display for computers and smart phones, Myopia is up over 70% globally in children under the age of 19 and in countries like China and Korea they are calling this an Epidemic.

Healthe has created EyeSafe™ technologies that are used in consumer devices, workplace environments, schools and leading eye care facilities including family practices and Lasik centers. A proprietary organic dye combination absorbs the dangerous High Energy Visible (HEV) blue light emissions while maintaining image clarity. EyeSafe products are available as screen covers or embedded directly in digital screens or virtual reality headsets.

We are serving with a global purpose to provide digital light protection for our customers and others in need of proper vision care. We are proud to have partnered with Prevent Blindness to help children and families that are in need for eye health care, treatment and financial assistance.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Introduction to eyesafe

  1. 1. Introduction to Eyesafe™ Improving health in a digital world | Health-e.com | Eyesafe.com MEMBER OF
  2. 2. Our Mission & Vision Our Mission In partnership with the medical community, our mission is to design and develop health-first products, technologies and standards to protect a global audience Our Vision 1.  To be the global brand with Eyesafe™ representing protection from digital light exposure  2.  To be the Doctor Recommended answer to each and every category we enter 3.  To be the integrated health technology in the manufacturing of all digital devices 4.  To be the source looked to for education around emerging technologies   5.  To be the brand that protects youth throughout childhood and their academic career  6.  To be recognized as the the company the health and medical community turns to design products around light technology Our Mission & Vision
  3. 3. Screen time health impact is a major concern •  1/3 adults now spend more time in front of devices than sleeping (9+ hours/day) (1) •  1/4 children now spend more than three hours in front of devices daily (1) •  Millions are impacted by symptoms of computer vision syndrome or digital eye strain (1) •  Research now connects exposure to blue light from screens with melatonin suppression, productivity loss, and long-term vision issues like AMD and cataracts (1, 5, 10)
  4. 4. “HEV light emitted by digital devices increases eye strain more than other colors in the spectrum that have a longer wavelength. Blue light can reach deeper into the eye than ultraviolet light and may damage the retina. Emerging research points to a link between blue-light exposure and AMD and cataracts” “The use of digital electronic devices can cause eyestrain symptoms including sore, tired, burning, dry eyes and headaches among other issues.” “Our data strongly suggests that improving the visual status of workers using computers results in greater productivity in the workplace, as well as improved visual comfort” “Blue light exposure suppressed melatonin for about twice as long as green light and shifted circadian rhythms by twice as much. Blue wavelengths seem to be the most disruptive at night.” “It is well established that short-wavelength or “blue” light is the most melatonin-suppressive; this is they type of light typically emitted by devices such as televisions, computer screens, and cellphones. This means that products such as tablets, smartphones, and other devices with self-luminous electronic displays are major sources for suppressing melatonin at night, thereby reducing sleep duration and disrupting sleep.” “Studies have shown that blue frequencies similar to what we are exposed to with LED from tablets and smartphones are 50-80 times more efficient in causing photoreceptor death than green light. The Paris study showed a 25x greater potential of retinal receptor damage over time.” “Blue rays of the spectrum seem to accelerate AMD more than other rays in the spectrum. Blue light directly penetrates the macular pigment of the eye, causing retinal damage.” Computer Vision Syndrome and Workplace Productivity Circadian Rhythm Disruption and Melatonin Suppression Long Term Retinal Damage Research reveals three major areas of concern
  5. 5. •  Blue light or high-energy visible light, is a particularly intense light wave emitted in the 380-500nm range •  Many LED screens peak in the 450-465nm blue light range •  Current screen covers to not block UV and HEV •  The majority of HEV blue goes straight to the back of the retina, which is especially harmful for children’s developing eyes Device Emissions from a Leading Tablet (Before & After Eyesafe) HEV Blue Light Reaches the Back of the Retina LED screens peak in the HEV blue light range
  6. 6. 18 MEMBER OF Our Value Proposition Eyesafe technology and products are the best way to protect your eyes from the harmful effects of digital blue light   Technology Product Market Value Proposition Model Strategic Advantage •  Eyesafe technology selectively reduces light while maintaining high transmission levels •  Eyesafe RPF60 and RPF30 products are world-class solutions for blue light blocking •  Massive market opportunities with Ophthalmic and Corporate markets prioritized •  OEM and licensing expansion •  Protect eyes from the harmful effects of blue light with a screen cover or device-integrated solution •  recommended by eye doctors •  High gross margin business (64- 70% currently) with pipeline filled via distributors and direct relationships •  IP and supply chain know-how exclusivity, brand recommended by leading eye doctors and organizations The problem of digital light exposure is growing in scale and awareness level. The mission of Healthe is to design and develop health-first products and technologies to improve health in a digital world.  
  7. 7. 18 MEMBER OF Eyesafe RPF™ - Sunscreen For Your Eyes GREEN  HUE   BLUE  HUE   CLEAR   Blue  Light  Blocking   %  (380  -­‐  1400  nm)   Visible  Light   Transmission   (400  -­‐  780)   19%   80%   Blue  Light  Blocking   %  (380  -­‐  1400  nm)   Visible  Light   Transmission   (400  -­‐  780)   31%   65%   Blue  Light  Blocking   %  (380  -­‐  1400  nm)   Visible  Light   Transmission   (400  -­‐  780)   68%   55%   Highest  emission  coverage  on       the  market  –  Dr  Recommended   Excellent  visibility                                             &  overall  efficacy       Excellent  for  consumers  who   really  value  their  color.      
  8. 8. •  Eyesafe RPF15 blocks 99% of UV light and 15% of HEV blue light with a clear film or adhesive •  Eyesafe RPF30 blocks 99% of UV light and 30% of HEV blue light with a slightly tinted film or adhesive •  Eyesafe RPF60 blocks 99% of UV light and 60% of HEV blue light with a tinted film or adhesive Eyesafe Retina Protection Factor (RPF) Blocks HEV •  Like suncreen, the Eyesafe Retina Protection Factor (RPF) level corresponds to amount of HEV blue light being blocked, pinpointing areas of concern •  Other technology covers only portions of the light spectrum (UV) or blankets the entire spectrum •  IP holdings cover screen cover, screen replacement and OEM applications
  9. 9. Numerous eye doctors are now recommending Eyesafe to patients including: Dr. Ralph Chu, MD Dr. Gina Wesley, OD Dr. Mike Novak, OD Dr. Sheri Rowen, MD Dr. Chad Dockter, OD Dr. Lynn Sulerud, OD Dr. Chris Freed, OD Dr. Robert Weinstock, MD Dr. Mike Nagel, OD Dr. William Trattler, MD Our leading ophthalmic partners include: Healthe is donating a percentage of revenue from product sold to Prevent Blindness and Star Pupils for children’s vision support and research. Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to saving sight. Eyesafe is now recommended by leading eye doctors Dr. David Friess, OD
  10. 10. Eyesafe uniquely blocks HEV blue and UV light with organic dye formulations, compared to other offerings with little to no blue light coverage * Tested with a spectrometer for device emissions with Eyesafe and other screen covers * * Uniquely blocking UV and HEV blue light
  11. 11. Applied as a film layer or embedded in pressure sensitive adhesive (PSA) to block HEV blue and UV Embedded in a film layer or mixed with PSA for device integration including personal electronics, laptops and monitors Applied as a lens technology uniquely providing significant HEV blue light coverage while maintaining high overall transmission TM SCREEN COVERS OEM LENS -  Ophthalmic -  Chiropractic -  Enterprise -  Education -  E-Commerce -  Retail -  Ophthalmic -  Chiropractic -  Enterprise -  Education -  E-Commerce -  Ophthalmic -  Chiropractic -  Retail -  E-Commerce Eyesafe Technology and IP have Various Applications Markets Notes
  12. 12. Learn more at Eyesafe.com!
  13. 13. UV & HEV Light Impact Research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
  14. 14. UV & HEV Light Impact Research (2) F* O#**!C+%+#! 0*6:#&$6+;! G%.*-4*.I.7$.,%* _.&7("9.83*J44./(%* Q8..>@*O",/7$"7#* ("5"#&@*7#$* 78.,(#.%%* Y'.*1%.*-4*$"&"(78*$.9"/.%*C.4-,.*C.$("5.*>,-8-#&%*('.*("5.*"(*(7D.%*(-*4788* 7%8..>@*$.873%*('.*/",/7$"7#*/8-/D@*%1>>,.%%.%*8.9.8%*-4*('.*%8..>L>,-5-("#&* '-,5-#.*5.87(-#"#@*,.$1/.%*('.*75-1#(*7#$*$.873%*('.*("5"#&*-4*I2:* %8..>@*7#$*,.$1/.%*78.,(#.%%*('.*4-88-?"#&*5-,#"#&A* >#7%A-,&K/-#(.#(KEEMKUKEMSMA 7C%(,7/(* * ;* 0PCP!M%+6)*%9! 56=&%&;!)/! I#26'6*#! Y'.*G#"`1.*!.78('* 244./(%*-4*X81.* ]"&'(* X81.*8"&'(*.R>-%1,.*/7#*$"%,1>(*/",/7$"7#*,'3('5** #/C"A#85A#"'A&-9K>5/K7,("/8.%K +:OMFSE;FTK* * ! K'>9%&!3#%9+(D!QI8!%*2!H%+%&%'+$!! ! C)>&'#! G6+9#! 3#%9+(!,-.%'+!M)+#$! 56*F! E<* 4*:6&)*-#*+%9! 3#%9+(! O#&$.#'+6:#$! 548$!%*2!"#+6*%9! ,*R>&;!6*!%!"%+! I)2#9!! Y'.*,.%18(%*-4*('.*>,.%.#(*%(1$3*"#$"/7(.*('7(*.R>-%1,.*(-*]26*8"&'(*"#*('"%* 78C"#-*,7(*5-$.8*/7#*"#$1/.*,.("#78*$757&.*7%*.9"$.#/.$*C3*('.*41#/("-#78* 2Ia*%(1$3@*Z!O@*YG_2]@*7#$*Y2:*.R75"#7("-#%A*B1,*,.%18(%*78%-*%1&&.%(* ('7(*('"%*,.("#78*$757&.*/-18$*C.*,.87(.$*(-*C81.*8"&'(b"#$1/.$*-R"$7("9.* %(,.%%*?"('"#*('.*,.("#78*("%%1.%@*7%*.9"$.#/.$*C3*('.*IBQ*&.#.,7(.$*"#*('.* ,.("#7*74(.,*]26*8"&'(*.R>-%1,.c*C81.*8"&'(*.R>-%1,.*573*/15187("9.83* "#$1/.*>'-(-,./.>(-,*8-%%A* #(.A*6#($A*6(A7):KAJ@S?TLK* * EE* O4HQQ! 341!%*2!O)+#*+6%9! K'>9%&!8%-%7#! Q(1$".%*'79.*%'-?#*('7(*$..>.,*C81.*4,.`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c*('"%*C81.*8"&'(*/-,,.%>-#$%*(-*7* D#-?#*%>./(,15*4-,*,.("#78*'7d7,$%A* #/C"A#85A#"'A&-9K>1C5.$KMET <<S<<* * ES* "#:6#W!)/! K.+)-#+&;! G(#!5)W2)W*!)*! E9>#!567(+! GH*7#$*!2H*8"&'(*4,-5*$.9"/.%*$757&"#&*,.("#7@*7%%-/"7(.$*?"('*7&.* ,.87(.$*57/187,*$.&.#.,7("-#@*4-,57("-#*-4*/7(7,7/(*/.88*8"4.@*$757&.*(-* ,.("#78*/.88%A*!2HKC81.*8"&'(*"5>7/("#&*C7/D*-4*('.*.3.*eJ:6f*?'"8.*GH* "5>7/("#&*4,-#(*-4*.3.*e/7(7,7/(*4-,57("-#fA* ,.9".?-4->(-5.(,3A/-5K/-#(" #1"#&.$1/7("-#K(7C9".?(.%(K 8.%%-#"$KE<;^UUK* * EU* K.+)-#+&6'! I%*%7#-#*+! C(#226*7!567(+!)*! +(#!E9>#!567(+! C.#'+&>-!! ! X81.*8"&'(*%/".#("4"/7883*,./-&#"d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
  15. 15. UV & HEV Light Impact Research (3) | Improving health in a digital world | © 2014 DigiHealth LLC. All rights reserved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d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g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
  16. 16. Contact: Justin Barrett, Chief Executive Officer Justin@Health-e.com 612.619.3302 Eyesafe.com

×